Clinicopathological features and BRAFV600E mutations in patients with isolated hypothalamic-pituitary Langerhans cell histiocytosis

Table 1 Clinical profile and follow-up data of seven patients with hypothalamic-pituitary Langerhans cell histiocytosis

No.	Age (years)/ Gender	The interval between onset of symptoms and diagnosis	CDI	Sites of involvement		Follow-up	Therapy
No.		(months)	CDI	At presentation	Follow-up	Follow-up	Therapy
1	9 / Female	108	Present	PS	None	Alive, 39 ms	RT + HRT
2	47 / Female	1	Present	PS	PS	Alive, 5 ms	HRT
3	12 / Female	36	Present	PS + H	PS + H	Alive, 5 ms	HRT
4	22 / Male	2	Present	PS + P	NA	NA	NA
5	13 / Male	4	Present	PS + H	None	Alive, 41 ms	RT + HRT
6	15 / Male	1	Present	PS + P	PS + P	Alive, 2 ms	HRT
7	35 / Female	18	Present	PS	Liver involvement suspected	Died, 74 ms	RT + Surgery + HRT

PS pituitary stalk, H hypothalamus, P pituitary, NA not available, RT radiotherapy, CDI central diabetes insipidus, HRT hormone replacement therapy

ISSN: 1746-1596